May 18--Osteoporosis is still considered a disease of older white women, but it
is clear that both sexes and all ethnic groups have some risk for fracture,
explains Dr Adnan Abdulwahid, Rheumatologist, Zulekha Hospital, Sharjah.
Thus, even though women fracture more often, those men who experience hip
fracture are vulnerable.
While the risk for fracture in men increases with age, as it does in women,
there is a subgroup of men who present in middle age usually with vertebral
fractures. Some men may have chronic obstructive pulmonary disease, inflammatory
bowel disease, or a rheumatologic condition requiring oral glucocorticoids.
Reasons and risk factors for low BMD (Bone Mineral Density) in older men.
--Low body weight
--Decreased physical activity
--Previous adult fracture
Owing to the increasing fracture risk with aging, screening men in risk of
osteoporosis by dual energy X-ray absorptiometry (DXA) of the spine and hip is
advisable. Men at increased risk for osteoporosis should undergo bone mineral
density (BMD) testing using central dual-energy X-ray absorptiometry (DXA).
For men aged 50 and above, one in five will experience an osteoporosis-related
fracture in their lifetime.
Specific recommendations include the followings:
--Men at higher risk for osteoporosis should undergo bone density testing using
DXA, as well as laboratory testing to detect contributing causes.
--Recommended daily calcium intake for men who are at risk for osteoporosis is
1000 to 1200 mg. Ideally, dietary sources would suffice, but calcium supplements
may be added if needed.
--Men at higher risk for osteoporosis should be encouraged to participate in
weight-bearing exercise and to avoid smoking and excessive alcohol.
--Men with vitamin D levels lower than 30 ng/mL should receive vitamin D
supplementation with a target level of 30 ng/mL or greater.
--Pharmacotherapy for osteoporosis is indicated for men at least 50 years of age
with a history of spine or hip fractures, and for men at high risk for fracture
resulting from low BMD (T-scores of −2.5 or below) and/or clinical risk
--Selection of therapeutic agent should be individualised based on
patient-specific factors including fracture history, severity of osteoporosis
(T-scores), risk for hip fracture, patterns of BMD, comorbid conditions (such as
peptic ulcer disease, gastroesophageal reflux, malabsorption syndromes,
malignancy), cost, and other factors.
--To determine treatment response, clinicians should monitor BMD by serial DXA
at the spine and hip every 1 to 2 years in men receiving pharmacotherapy for
(c)2013 the Khaleej Times (Dubai, United Arab Emirates)
Visit the Khaleej Times (Dubai, United Arab Emirates) at www.khaleejtimes.com
Distributed by MCT Information Services